Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia

Inherited genetic variation is associated with 6-mercaptopurine (6-MP) dose reduction and frequent toxicities induced by 6-MP. However, the tolerable dose for 6-MP is not fully predicted by the known variation in NUDT15 and TPMT among Asian children with acute lymphoblastic leukaemia (ALL). We performed a genome-wide association study (GWAS) related to 6-MP dose among Japanese children with ALL. This GWAS comprised 224 patients previously enrolled in Tokyo Children's Cancer Study Group clinical studies with replication attempted in 55 patients. Genome-wide single nucleotide polymorphism (SNP) genotypes were evaluated for association with average 6-MP dose during the initial 168 days of maintenance therapy. Possible associations were observed across five gene-coding regions, among which only variants at 13q14.2 were significant and replicated genome-wide (rs116855232, NUDT15, beta = -10.99, p = 3.7 x 10(-13)). Notable findings were observed for variants in AFF3 (rs75364948, p = 2.05 x 10(-6)) and CHST11 (rs1148407, p = 2.09 x 10(-6)), but were not replicated possibly due to small numbers. A previously reported candidate SNP in MTHFR was associated with higher average 6-MP dose (rs1801133, p = 0.045), and FOLH1 (rs12574928) was associated in an evaluation of candidate regions (p(adjust) = 0.013). This study provides strong evidence that rs116855232 in NUDT15 is the genetic factor predominantly associated with 6-MP tolerable dose in children in Japan

Additional file 1 of Time trends in emotional well-being and self-esteem in children and adolescents during the COVID-19 pandemic

Additional file 1: Figure S1. Sample selection procedure. Table S1. Sociodemographic characteristics. Table S2. Weighted adjusted estimates of emotional well-being and self-esteem, excluding three municipalities participating in wave 3. Table S3. Weighted adjusted estimates of emotional well-being and self-esteem, excluding participants who reported having answered previous surveys (information only available in wave 3). Table S4. Weighted adjusted estimates and differences in emotional well-being and self-esteem, stratified by age (Fig. 2). Table S5. Weighted adjusted estimates and differences in emotional well-being and self-esteem stratified by gender (Fig. 2). Table S6. Associations between the Stringency Index and mental health outcomes and coefficients of multiplicative interaction terms between the Stringency Index and age group and gender

Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia

Inherited genetic variation is associated with 6-mercaptopurine (6-MP) dose reduction and frequent toxicities induced by 6-MP. However, the tolerable dose for 6-MP is not fully predicted by the known variation in NUDT15 and TPMT among Asian children with acute lymphoblastic leukaemia (ALL). We performed a genome-wide association study (GWAS) related to 6-MP dose among Japanese children with ALL. This GWAS comprised 224 patients previously enrolled in Tokyo Children's Cancer Study Group clinical studies with replication attempted in 55 patients. Genome-wide single nucleotide polymorphism (SNP) genotypes were evaluated for association with average 6-MP dose during the initial 168 days of maintenance therapy. Possible associations were observed across five gene-coding regions, among which only variants at 13q14.2 were significant and replicated genome-wide (rs116855232, NUDT15, beta = -10.99, p = 3.7 x 10(-13)). Notable findings were observed for variants in AFF3 (rs75364948, p = 2.05 x 10(-6)) and CHST11 (rs1148407, p = 2.09 x 10(-6)), but were not replicated possibly due to small numbers. A previously reported candidate SNP in MTHFR was associated with higher average 6-MP dose (rs1801133, p = 0.045), and FOLH1 (rs12574928) was associated in an evaluation of candidate regions (p(adjust) = 0.013). This study provides strong evidence that rs116855232 in NUDT15 is the genetic factor predominantly associated with 6-MP tolerable dose in children in Japan